MXPA05002337A - Formulacion medicinal en aerosol, estabilizada con agua. - Google Patents

Formulacion medicinal en aerosol, estabilizada con agua.

Info

Publication number
MXPA05002337A
MXPA05002337A MXPA05002337A MXPA05002337A MXPA05002337A MX PA05002337 A MXPA05002337 A MX PA05002337A MX PA05002337 A MXPA05002337 A MX PA05002337A MX PA05002337 A MXPA05002337 A MX PA05002337A MX PA05002337 A MXPA05002337 A MX PA05002337A
Authority
MX
Mexico
Prior art keywords
medicinal aerosol
related applications
aerosol formulation
water stabilized
stabilized medicinal
Prior art date
Application number
MXPA05002337A
Other languages
English (en)
Spanish (es)
Inventor
Anthony Cutie
Original Assignee
Kos Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kos Life Sciences Inc filed Critical Kos Life Sciences Inc
Publication of MXPA05002337A publication Critical patent/MXPA05002337A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MXPA05002337A 2002-09-03 2003-09-03 Formulacion medicinal en aerosol, estabilizada con agua. MXPA05002337A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/234,825 US7074388B2 (en) 1998-12-10 2002-09-03 Water stabilized medicinal aerosol formulation
PCT/US2003/027245 WO2004022035A1 (en) 2002-09-03 2003-09-03 Water stabilized medicinal aerosol formulation related applications

Publications (1)

Publication Number Publication Date
MXPA05002337A true MXPA05002337A (es) 2005-12-05

Family

ID=31977472

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05002337A MXPA05002337A (es) 2002-09-03 2003-09-03 Formulacion medicinal en aerosol, estabilizada con agua.

Country Status (9)

Country Link
US (1) US7074388B2 (https=)
EP (1) EP1569617A4 (https=)
JP (1) JP2006502160A (https=)
AU (1) AU2003272251A1 (https=)
CA (1) CA2497171C (https=)
DE (1) DE03754425T1 (https=)
ES (1) ES2247959T1 (https=)
MX (1) MXPA05002337A (https=)
WO (1) WO2004022035A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006384B1 (ru) * 2000-07-31 2005-12-29 Нюкомед Данмарк А/С Композиция фентанила для интраназального введения
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
DK1608336T3 (da) * 2003-03-20 2008-06-02 Boehringer Ingelheim Pharma Formulering til en doseringsinhalator med hydrofluorakaner som drivmidler
CA2522231A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
US8551534B2 (en) 2007-10-10 2013-10-08 Parion Sciences, Inc. Inhaled hypertonic saline delivered by a heated nasal cannula
EP2477601B1 (en) * 2009-09-15 2017-09-13 Union Carbide Chemicals & Plastics Technology LLC Personal care compositions with ethylene acrylic acid copolymer aqueous dispersions
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2012061195A2 (en) 2010-11-04 2012-05-10 Union Carbide Chemicals & Plastics Technology Llc Skin care compositions
US8778383B2 (en) 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
ES2792682T3 (es) 2014-02-10 2020-11-11 Respivant Sciences Gmbh Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS
CA3100679A1 (en) 2018-06-08 2019-12-12 Toko Yakuhin Kogyo Co., Ltd. Fluticasone furoate nasal preparation composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6447750B1 (en) * 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6565833B1 (en) * 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6548049B1 (en) * 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation

Also Published As

Publication number Publication date
US20030091512A1 (en) 2003-05-15
US7074388B2 (en) 2006-07-11
WO2004022035A1 (en) 2004-03-18
EP1569617A1 (en) 2005-09-07
DE03754425T1 (de) 2006-03-09
ES2247959T1 (es) 2006-03-16
CA2497171A1 (en) 2004-03-18
AU2003272251A1 (en) 2004-03-29
CA2497171C (en) 2009-04-28
EP1569617A4 (en) 2010-10-27
JP2006502160A (ja) 2006-01-19

Similar Documents

Publication Publication Date Title
MXPA05002337A (es) Formulacion medicinal en aerosol, estabilizada con agua.
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
MXPA03000442A (es) Una formulacion medicinal en aerosol.
EP1135173A4 (en) MEDICINAL AEROSOL FORMULATION
IL164699A (en) Derivatives of diketohydrazine compounds and pharmaceutical compositions and medicaments containing the compounds as the active ingredient
IL138767A0 (en) Anticancer compositions
EA200600696A1 (ru) Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
IL168266A (en) Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments
DK0717617T3 (da) Mikropartikler indeholdende aktive bestanddele og gas
ATE291898T1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
EA200500909A1 (ru) Модифицированное высвобождение фармацевтической композиции
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
WO2004091591A3 (fr) Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives
WO2005065639A3 (en) Novel pharmaceutical compositions
DK1355906T3 (da) 2H-1-benzopyranderivater, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende dem
WO2002007672A3 (en) A medicinal aerosol formulation
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
WO2002000191A3 (de) Bdellosomen
AP2001002369A0 (en) Pharmaceutical complex.
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
MXPA01008348A (es) Microcapsulas para la liberacion prolongada de farmacos.
WO2001039741A3 (de) Mitomycin c-lösung